-+ 0.00%
-+ 0.00%
-+ 0.00%

Changchun Hi-Tech announced that its subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration. The application for registration of a domestically produced drug for injectable GenSci 136 was approved, and clinical trials were agreed to be carried out. The indication was systemic lupus erythematosus, and the acceptance number was CXSL2600764. This drug is a class 1 biological product for therapeutic use.

Zhitongcaijing·09/28/2026 10:01:20
Listen to the news
Changchun Hi-Tech announced that its subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration. The application for registration of a domestically produced drug for injectable GenSci 136 was approved, and clinical trials were agreed to be carried out. The indication was systemic lupus erythematosus, and the acceptance number was CXSL2600764. This drug is a class 1 biological product for therapeutic use.